Can an oral chemo pill boost breast cancer treatment?

NCT ID NCT07739511

First seen Jul 31, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This trial is testing an oral form of the chemotherapy drug paclitaxel, given alongside standard anti-HER2 therapies (trastuzumab and pertuzumab), for people with HER2-positive breast cancer. The goal is to find the safest and most effective dose of the oral paclitaxel when used before surgery. Participants will receive six cycles of this combination, and the study will monitor for side effects and how well the tumor responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Paclitaxel oral solution combined with trastuzumab and pertuzumab (THP regimen)
What this could lead to
If successful, this could offer a more convenient oral chemotherapy option for HER2-positive breast cancer, potentially improving treatment response before surgery.
What could go wrong
This is an early-phase dose-finding trial with a small number of participants, so the optimal dose and effectiveness are not yet confirmed. Side effects of chemotherapy, such as nerve damage or low blood counts, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Affiliated Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, Guizhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.